Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- peptide NF-kB signal transduction intracellular signaling inflammation transcription factor biochemical NFkB NF-?B NF?B negative control
- Product Overview:
NF-?B inhibitor (Item No. 17493) is a synthetic peptide corresponding to the nuclear localization sequence (NLS) of NF-?B p105 subunit (also known as p50) appended to a hydrophobic sequence to facilitate import into living cells.{17866} It blocks the nuclear import of p105 in cells treated with activators of NF-?B signaling, including LPS and TNF-?.{17866} NF-?B control is a peptide that is identical in sequence to NF-?B inhibitor, except two essential, basic residues of the p105 NLS are substituted with non-basic amino acids.{17866} It is ineffective at blocking the activation of NF-?B signaling and is used as a negative control peptide.{17866,28515,28513}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.